A recent answer by Commissioner Olivér Várhelyi reveals the European Commission’s intention to provide a comprehensive cost-benefit analysis regarding the proposed 12-month extension to the Supplementary Protection Certificate (SPC) under the newly proposed European Biotech Act. This policy move, which impacts pharmaceutical companies, healthcare payers, generic and biosimilar drug manufacturers, and EU consumers, is expected to provoke notable reactions particularly within the pharmaceutical and healthcare sectors due to potential shifts in market exclusivity and healthcare spending.
The response addresses a parliamentary question posed by MEP Tiemo Wölken from the Socialists & Democrats (S&D) group, who asked for detailed information on the economic and healthcare budget impacts of the SPC extension introduced in Article 27 of the European Biotech Act (COM(2025)1022). Wölken also questioned whether alternative incentive mechanisms had been evaluated by the Commission.
Commissioner Várhelyi's reply states that a Staff Working Document will be published, containing the anticipated cost-benefit analysis of the Act’s measures, including the SPC extension, in alignment with the Commission’s Better Regulation Guidelines. The document aims to clarify the economic implications of extending patent protection periods for biotechnologically developed and advanced therapy medicinal products but does not specify new regulatory instruments or measurable targets beyond this analysis.
Policy-wise, the Commission appears to maintain its approach favoring the SPC extension as a targeted incentive enhancing intellectual property protection, presumably to stimulate biotech innovation. This entails a trade-off between potentially increased healthcare expenditure due to delayed generic and biosimilar entries versus stronger market protection for biotech products.
For stakeholders, pharmaceutical companies could benefit from extended exclusivity, potentially justifying their innovation investments. Conversely, healthcare systems and payers might face higher drug costs and budget pressures from postponed generic competition. Generic and biosimilar manufacturers would experience delayed market access, while patients risk prolonged exposure to higher prices.
Institutionally, this response indicates that further detailed assessments are forthcoming as part of the Commission’s regulatory process. The upcoming Staff Working Document will provide essential insights to inform EU policymakers and stakeholders about the balance between innovation incentives and access to medicines within the evolving biotech regulatory framework.
← Atlas › News › Industry, Innovation and Internal Market